Michael Ryskin
BofA Securities, Research Division

My name is Mike Ryskin. I'm on the Bank of America Life Science Tools and Diagnostics team, and we're excited to be joined by Bio-Techne. We're pleased to host Kim Kelderman, Chief Executive Officer; and Jim Hippel, Chief Financial Officer. Kim, Jim, thanks for being here.

Kim Kelderman
CEO, President & Director

Great. Thanks for having us.

Michael Ryskin
BofA Securities, Research Division

Format will be a fireside chat, but raise your hand if you've got a burning question. I mean maybe just to kick things off, you recently reported, any highlights from the quarter you'd like to talk through sort of how it played out relative to expectations? What was a little bit better, what was a little bit worse?

Kim Kelderman
CEO, President & Director

Yes. So yes, we reported our Q3 and printed negative 2% growth for the quarter, and that was over a prior year quarter of about 6% growth. A couple of dynamics in there that we'll definitely double-click on. But in a quarter like that, you always want to look back and ask yourself, do you have the right strategy and is it rolling out in the right pace? And there, I've been pleased to see that, as you know, our strategy is around having a really broad core that reads on many different end markets, and that gives us the leverage to pick specific fast-growing vertical markets where we can build out full solutions in specific application spaces. And for us, that's cell therapy, it's protein analytics and it's spatial biology.